IB
Immorta Bio develops personalized regenerative therapies using autologous pluripotent stem cells to create young, patient-specific progenitor cells for organ rejuvenation and immune enhancement. The company targets diseases of aging, including cancer and organ failure, by addressing the underlying cellular deterioration associated with aging.
Updated 4 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- Immorta Bio develops personalized regenerative therapies using autologous pluripotent stem cells to create young, patient-specific progenitor cells for organ rejuvenation and immune enhancement. The company targets diseases of aging, including cancer and organ failure, by addressing the underlying cellular deterioration associated with aging.